Serum levels of placental growth factor reflect the severity of retinopathy of prematurity
Authors:
- 10 June 2021
- journal article
- research article
- Published by Wiley in Acta Paediatrica
- Vol. 110 (10) , 2778-2779
Abstract
Retinopathy of prematurity (ROP) is a neovascular disorder of the immature retina and a leading cause of preventable blindness worldwide.1 A two-phase hypothesis for ROP pathogenesis has been suggested.1 Phase one is vaso-obliteration, where physiological vascularity is compromised and retinal vascular development is delayed by a hyperoxic environment. This induces vasoconstriction, with decreased levels of vascular endothelial growth factor (VEGF) and insulin growth factor-1. Phase two is vasoproliferation, where the avascular retina becomes hypoxic and releases angiogenic factors.Keywords
This publication has 5 references indexed in Scilit:
- Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurityScientific Reports, 2020
- The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseasesProgress in Retinal and Eye Research, 2019
- Systemic Inflammation-Associated Proteins and Retinopathy of Prematurity in Infants Born Before the 28th Week of GestationInvestigative Ophthalmology & Visual Science, 2017
- Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity InfantsInvestigative Ophthalmology & Visual Science, 2016
- Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurityJournal of Clinical Investigation, 2003